Two Sigma Advisers’s Myriad Genetics MYGN Stock Holding History

Two Sigma Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-340,200	Closed	-$2.09M	–	1362
2025 Q4	$2.09M	Buy	340,200 +6,800	+2%	+$49.3K	﹤0.01%	1169
2025 Q3	$2.41M	Buy	333,400 +45,400	+16%	+$270K	﹤0.01%	1053
2025 Q2	$1.53M	Buy	+288,000	New	+$1.7M	﹤0.01%	1247
2024 Q3	–	Sell	-10,800	Closed	-$264K	–	2436
2024 Q2	$264K	Sell	10,800 -7,000	-39%	-$154K	﹤0.01%	2123
2024 Q1	$379K	Sell	17,800 -4,200	-19%	-$90.3K	﹤0.01%	1980
2023 Q4	$421K	Sell	22,000 -9,600	-30%	-$166K	﹤0.01%	1986
2023 Q3	$507K	Buy	31,600 +10,100	+47%	+$192K	﹤0.01%	1787
2023 Q2	$498K	Sell	21,500 -3,300	-13%	-$72K	﹤0.01%	1807
2023 Q1	$576K	Sell	24,800 -8,100	-25%	-$165K	﹤0.01%	1884
2022 Q4	$477K	Sell	32,900 -2,400	-7%	-$44.7K	﹤0.01%	1897
2022 Q3	$674K	Sell	35,300 -6,700	-16%	-$154K	﹤0.01%	1718
2022 Q2	$763K	Sell	42,000 -15,700	-27%	-$326K	﹤0.01%	1726
2022 Q1	$1.45M	Sell	57,700 -19,300	-25%	-$494K	﹤0.01%	1429
2021 Q4	$2.13M	Sell	77,000 -50,500	-40%	-$1.46M	0.01%	1163
2021 Q3	$4.12M	Sell	127,500 -256,700	-67%	-$8.52M	0.01%	890
2021 Q2	$11.7M	Sell	384,200 -213,400	-36%	-$6.17M	0.03%	503
2021 Q1	$18.2M	Sell	597,600 -130,700	-18%	-$3.71M	0.05%	386
2020 Q4	$14.4M	Sell	728,300 -128,300	-15%	-$2.07M	0.04%	441
2020 Q3	$11.2M	Buy	856,600 +238,700	+39%	+$3.02M	0.03%	501
2020 Q2	$7.01M	Buy	617,900 +511,500	+481%	+$7.26M	0.02%	678
2020 Q1	$1.52M	Buy	+106,400	New	+$2.25M	0.01%	1257
2019 Q3	–	Sell	-11,900	Closed	-$331K	–	2340
2019 Q2	$331K	Buy	+11,900	New	+$336K	﹤0.01%	1976
2019 Q1	–	Sell	-7,800	Closed	-$227K	–	2397
2018 Q4	$227K	Buy	+7,800	New	+$281K	﹤0.01%	2091
2018 Q2	–	Sell	-9,698	Closed	-$287K	–	2447
2018 Q1	$287K	Sell	9,698 -270,614	-97%	-$9.16M	﹤0.01%	2033
2017 Q4	$9.63M	Sell	280,312 -226,548	-45%	-$7.64M	0.03%	626
2017 Q3	$18.3M	Sell	506,860 -34,430	-6%	-$982K	0.05%	390
2017 Q2	$14M	Sell	541,290 -281,822	-34%	-$5.98M	0.05%	417
2017 Q1	$15.8M	Sell	823,112 -224,755	-21%	-$3.98M	0.05%	424
2016 Q4	$17.5M	Buy	1,047,867 +399,784	+62%	+$7.23M	0.07%	326
2016 Q3	$13.3M	Buy	648,083 +180,684	+39%	+$4.58M	0.06%	351
2016 Q2	$14.3M	Buy	467,399 +128,200	+38%	+$4.45M	0.07%	290
2016 Q1	$12.7M	Buy	339,199 +10,700	+3%	+$403K	0.07%	297
2015 Q4	$14.2M	Buy	328,499 +68,800	+26%	+$2.91M	0.08%	263
2015 Q3	$9.73M	Buy	259,699 +1,700	+0.7%	+$60.3K	0.06%	334
2015 Q2	$8.77M	Buy	257,999 +20,900	+9%	+$711K	0.07%	327
2015 Q1	$8.39M	Sell	237,099 -100	-0%	-$3.58K	0.06%	356
2014 Q4	$8.08M	Sell	237,199 -168,600	-42%	-$5.98M	0.06%	347
2014 Q3	$15.7M	Sell	405,799 -81,900	-17%	-$3.06M	0.12%	202
2014 Q2	$19M	Sell	487,699 -139,500	-22%	-$5.19M	0.15%	167
2014 Q1	$21.4M	Buy	627,199 +247,600	+65%	+$7.67M	0.2%	120
2013 Q4	$7.96M	Buy	379,599 +278,000	+274%	+$7.03M	0.08%	273
2013 Q3	$2.39M	Buy	101,599 +93,880	+1,216%	+$2.67M	0.03%	562
2013 Q2	$207K	Buy	+7,719	New	+$224K	﹤0.01%	1956

Other funds holding MYGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Advisers's MYGN Position: Q1 2026 in Review

Two Sigma Advisers sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 340,200 shares — an estimated $2.09M sold.

Two Sigma Advisers first reported a position in MYGN in Q2 2013 and held it in 43 quarters. The position peaked at $21.4M in Q1 2014. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

Two Sigma Advisers reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
Two Sigma Advisers sold 340,200 Myriad Genetics shares in Q1 2026, an estimated $2.09M.
Two Sigma Advisers first reported a position in Myriad Genetics in Q2 2013 and held it in 43 quarters.
Two Sigma Advisers's Myriad Genetics position peaked at $21.4M in Q1 2014.
202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Two Sigma Advisers's 13F filing for Q1 2026.